Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Eli Lilly said its new weight-loss pill had cleared a late-stage clinical trial, a promising sign as the company continues to ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Once-weekly basal insulin combined with an intermittently scanned continuous glucose monitor reduced HbA1c and improved time ...

GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of dementia, suggesting these drugs may have a ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

LONDON/COPENHAGEN (Reuters) - Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish drugmaker said on Thursday.

Diabetes, Obesity and MASH therapeutic area at Novo Nordisk. “We are pleased to enter this agreement with Lexicon as it will allow us to explore a novel biology and potential treatment paradigm ...

Europe’s largest pharmaceutical firm, Novo Nordisk, saw its stocks tumble 27% in March, marking their worst monthly performance since July 2002. As of market close on 31 March, the Danish firm’s share ...